In the last trading session, 0.12 million shares of the Unity Biotechnology Inc (NASDAQ:UBX) were traded, and its beta was 0.78. Most recently the company’s share price was $1.73, and it changed around $0.04 or 2.37% from the last close, which brings the market valuation of the company to $29.15M. UBX currently trades at a discount to its 52-week high of $2.02, offering almost -16.76% off that amount. The share price’s 52-week low was $0.94, which indicates that the current value has risen by an impressive 45.66% since then. We note from Unity Biotechnology Inc’s average daily trading volume that its 10-day average is 0.48 million shares, with the 3-month average coming to 148.57K.
Unity Biotechnology Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended UBX as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Unity Biotechnology Inc is expected to report earnings per share of -0.4 for the current quarter.
Unity Biotechnology Inc (NASDAQ:UBX) trade information
Instantly UBX has showed a green trend with a performance of 2.37% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.8500 on recent trading dayincreased the stock’s daily price by 6.49%. The company’s shares are currently up 77.18% year-to-date, but still down -3.35% over the last five days. On the other hand, Unity Biotechnology Inc (NASDAQ:UBX) is 60.19% up in the 30-day period. We can see from the shorts that 0.24 million shares have been sold at a short interest cover period of 2.29 day(s).
Unity Biotechnology Inc (UBX) estimates and forecasts
Unity Biotechnology Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 17.69 percent over the past six months and at a 47.08% annual growth rate that is well above the industry average of 16.50%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 36.93%.
UBX Dividends
Unity Biotechnology Inc’s next quarterly earnings report is expected to be released in February.
Unity Biotechnology Inc (NASDAQ:UBX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.31% of Unity Biotechnology Inc shares, and 20.21% of them are in the hands of institutional investors. The stock currently has a share float of 20.48%.
Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Sep 30, 2024 . The former held 395.99 shares worth $0.69 million, making up 2.35% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 194.78 shares worth around $0.34 million, which represents about 1.16% of the total shares outstanding.
